CFN Media Exclusive Interview with United Cannabis: Developing Anti-Inflammatory Pharmaceuticals
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 09/20/17 -- CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an exclusive interview with (OTCQB: CNAB) Chief Science Officer Dr. Brent Reynolds, PhD. In the , Dr. Reynolds discusses the importance of clinical development and how the company''s recent acquisition of Prana Therapeutics plays into its overall strategy.
The medical cannabis industry is projected to reach $55.8 billion by 2025, according to , but that figure pales in comparison to the wider pharmaceutical market that''s worth more than $1 trillion per year. Despite the availability of medical marijuana at dispensaries, many people would rather see their primary care physician for treatments that have undergone extensive clinical trials to prove their safety and efficacy.
Prana Therapeutics'' Epidiferphane -- or EDP -- is a polymolecular botanical compound consisting of three botanical extracts with documented synergistic action. In pre-clinical trials, EDP has shown efficacy and preventing and treating several disease indications, including anemia, neutropenia, neuropathy, "chemo fog", arthritis, and brain tumors. The company is currently establishing clinical trials at several sites to evaluate EDP across several indications.
The company''s primary focus is on using EDP in combination with a low-carb diet to mitigate the effects of chemotherapy and improve outcomes in cancer patients. In particular, the therapy has been shown to reduce four major negative side effects of chemotherapy.
EDP works by decreasing inflammation, which is a common symptom across many different diseases. In combination with a low-carb diet and/or nutritional ketosis, the therapy has been shown to reduce levels of cytokines that contribute to inflammatory diseases, and in a small cohort of patients, has been reported to reduce pain, morning stiffness, and improve overall sleep, in patients with pain and/or arthritis.
United Cannabis has taken a unique approach to the cannabis industry. Rather than simply selling over-the-counter products, the company''s long-term goal is to develop its Prana products into a line of that physicians can prescribe to their patients. The company signed a letter of intent with the Caribbean Institute of Medical Research -- a full-service global CRO -- to move closer to achieving these goals.
United Cannabis the acquisition of a majority stake in Prana Therapeutics on July 20, 2017. Under the terms of the agreement, Prana will continue to operate independently but Dr. Brent Reynolds has already contributed his expertise in helping the company reach its goals.
The company that it was issued US Patent #9730911 granting it exclusive rights to its proprietary formulations based on compounds extracted from the cannabis plant. According to CEO Earnest Blackmon, the patent represents one of the cornerstones of its business plan that ultimately targets an FDA approval. The patent protects the use of suspending both phytocannabinoids and cannabinoids across many delivery mechanisms.
Dr. Brent Reynolds could also be instrumental in helping the company define its pathway through clinical trials. In addition, EDP could also be combined with Prana Bio products to develop complementary therapies since both have different mechanisms of action that accomplish the same goals of reducing inflammation.
In addition to its clinical approach to cannabis, United Cannabis Corp.''s majority acquisition of Prana Therapeutics opens the door to non-cannabis pharmaceuticals and could assist in pushing its own products through pre-clinical and clinical trials.
Learn how to become a CFN Media featured company, brand or entrepreneur:
Download the CFN Media iOS mobile app to access the world of cannabis from your smart phone:
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and , is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: .
CFN Media
Frank Lane
206-369-7050
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.09.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 1521397
Anzahl Zeichen: 2221
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Hospitals, Facilities and Providers
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 1173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CFN Media Exclusive Interview with United Cannabis: Developing Anti-Inflammatory Pharmaceuticals
"
steht unter der journalistisch-redaktionellen Verantwortung von
CFN Media (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
